Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraperitoneal and intravenous nab-paclitaxel plus S-1 for gastric cancer with peritoneal metastasis
ChiCTR1900025762Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paclitaxel and tegafur in gastric adenocarcinoma and gastric cancer (GC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Three-year overall survival rate. Planned start Sep 2019; status: not yet recruiting.
02
Drugs
paclitaxeltegafur
03
Conditions
gastric adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1900025762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900025762.